These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 32250313)

  • 1. Myasthenia Gravis Impairment Index: Sensitivity for Change in Generalized Muscle Weakness.
    de Meel RHP; Barnett C; Bril V; Tannemaat MR; Verschuuren JJGM
    J Neuromuscul Dis; 2020; 7(3):297-300. PubMed ID: 32250313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity of MG-ADL for generalized weakness in myasthenia gravis.
    de Meel RHP; Raadsheer WF; van Zwet EW; Verschuuren JJGM; Tannemaat MR
    Eur J Neurol; 2019 Jun; 26(6):947-950. PubMed ID: 30417962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the Italian version of the Myasthenia Gravis Impairment Index (MGII).
    Pasqualin F; Barnett C; Guidoni SV; Albertini E; Ermani M; Bonifati DM
    Neurol Sci; 2022 Mar; 43(3):2059-2064. PubMed ID: 34505205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myasthenia Gravis Impairment Index: Responsiveness, meaningful change, and relative efficiency.
    Barnett C; Bril V; Kapral M; Kulkarni AV; Davis AM
    Neurology; 2017 Dec; 89(23):2357-2364. PubMed ID: 29101274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-acceptable symptom states in myasthenia gravis.
    Mendoza M; Tran C; Bril V; Katzberg HD; Barnett C
    Neurology; 2020 Sep; 95(12):e1617-e1628. PubMed ID: 32759200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scales in the MGTX study.
    McPherson T; Aban I; Duda PW; Farzaneh-Far R; Wolfe GI; Kaminski HJ; Cutter G; Lee I;
    Muscle Nerve; 2020 Aug; 62(2):261-266. PubMed ID: 32369631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cigarette Smoking and Activities of Daily Living in Ocular Myasthenia Gravis.
    Gratton SM; Herro AM; Feuer WJ; Lam BL
    J Neuroophthalmol; 2016 Mar; 36(1):37-40. PubMed ID: 26457691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QMG and MG-ADL correlations: Study of eculizumab treatment of myasthenia gravis.
    Howard JF; Freimer M; O'Brien F; Wang JJ; Collins SR; Kissel JT;
    Muscle Nerve; 2017 Aug; 56(2):328-330. PubMed ID: 28010051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gender differences in clinical outcomes in myasthenia gravis: A prospective cohort study.
    Thomsen JLS; Vinge L; Harbo T; Andersen H
    Muscle Nerve; 2021 Nov; 64(5):538-544. PubMed ID: 34036597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study.
    Bril V; Howard JF; Karam C; De Bleecker JL; Murai H; Utsugisawa K; Ulrichts P; Brauer E; Zhao S; Mantegazza R; Vu T;
    Eur J Neurol; 2024 Jan; 31(1):e16098. PubMed ID: 37843174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of the Myasthenia Gravis Impairment Index.
    Barnett C; Bril V; Kapral M; Kulkarni A; Davis AM
    Neurology; 2016 Aug; 87(9):879-86. PubMed ID: 27402891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translation and validation of the arabic version of the myasthenia gravis activities of daily living scale.
    Alanazy MH; Abuzinadah AR; Muayqil T
    Muscle Nerve; 2019 May; 59(5):583-586. PubMed ID: 30697753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of outcome measures for myasthenia gravis subgroups.
    Luo Y; Dong X; Peng Y; Cui B; Yan C; Jin W; Li Y; Zhou R; Huang K; Yang H
    J Clin Neurosci; 2021 Sep; 91():270-275. PubMed ID: 34373039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychometric properties of MG-ADL items and MG-ADL score: An assessment of distributional characteristics, validity and factor structure in two large datasets.
    Janssen MF; Dewilde S; Wolfe GI; Muppidi S; Phillips G
    J Neurol Sci; 2024 Aug; 463():123135. PubMed ID: 39068745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measuring Overall Severity of Myasthenia Gravis (MG): Evidence for the Added Value of the MG Symptoms PRO.
    Regnault A; Morel T; de la Loge C; Mazerolle F; Kaminski HJ; Habib AA
    Neurol Ther; 2023 Oct; 12(5):1573-1590. PubMed ID: 37166675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity limitations in myasthenia gravis and relation to clinical variables.
    De Meel RHP; Lipka AF; Van Der Lende M; Van Zwet EW; Tannemaat MR; Verschuuren JJGM
    Muscle Nerve; 2017 Jul; 56(1):64-70. PubMed ID: 27859371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A population-based follow-up study of maximal muscle strength and mobility in patients with myasthenia gravis.
    Thomsen JLS; Vinge L; Harbo T; Andersen H
    Neuromuscul Disord; 2022 Apr; 32(4):305-312. PubMed ID: 35279342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics and impairment of activities of daily living among patients with myasthenia gravis with differing degrees of muscle weakness: a real-world study of patients in the US and five European countries.
    Pesa J; Choudhry Z; de Courcy J; Barlow S; Gibson G; Chatterton E; Birija SL; Hahn B; Govindarajan R
    BMC Neurol; 2024 Oct; 24(1):385. PubMed ID: 39395956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physician- and self-assessed myasthenia gravis activities of daily living score.
    Lee HL; Min JH; Seok JM; Cho EB; Cho HJ; Kim YD; Kim BJ
    Muscle Nerve; 2018 Mar; 57(3):419-422. PubMed ID: 28796382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Myasthenia Gravis-Activities of Daily Living (MG-ADL) and EQ-5D-5L Utility Values: The Additional Effect of Efgartigimod on Utilities.
    Dewilde S; Qi CZ; Phillips G; Iannazzo S; Janssen MF
    Adv Ther; 2023 Apr; 40(4):1818-1829. PubMed ID: 36867327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.